Search

Background/AimsThe current study evaluates the efficacy and safety of the stand-alone implantation of the MINIject (iSTAR Medical, Wavre, Belgium) supraciliary, microinvasive glaucoma drainage device in patients with medically uncontrolled open-angle glaucoma.MethodsThis prospective, multicentre, first-in-human, single-arm interventional study evaluated stand-alone, ab interno implantation in 25 patients of a 5 mm long uveoscleral device made of STAR biocompatible material, which is a soft, microporous, flexible silicone. The primary outcome was the reduction of intraocular pressure (IOP) at 6 months compared with baseline, and follow-up continued until 2 years for 21 patients. Secondary outcomes included success defined as diurnal IOP of ≤21 mmHg and >5 mmHg with an IOP reduction of 20% without (complete) or with/without (qualified) glaucoma medication.ResultsMean baseline IOP was 23.2±2.9 mmHg on 2.0±1.1 glaucoma medication ingredients and decreased to 13.8±3.5 mmHg (−40.7% reduction) on 1.0±1.3 medications 2 years after implantation. Complete success was achieved in 47.6% of patients (10/21) and qualified success in 100% of patients (21/21) at the 2-year follow-up. All patients achieved a 20% IOP reduction with 48% of patients medication-free. No serious ocular adverse events or additional glaucoma surgery were reported. Mean central endothelial cell density (ECD) mildly decreased from 2411 cells/mm2 (n=26) to 2341 cells/mm2 (n=21) at 24 months, which represents a 5% decrease for matched eyes. No patient had a ≥30% decrease in central ECD.ConclusionThis first-in-human study on the stand-alone implantation of the MINIject supraciliary drainage system shows promising IOP-lowering results and medication reduction over 24 months with few adverse events.Trial registration numberNCT03193736.

To evaluate the agreement of intraocular pressure (IOP) and central corneal thickness (CCT) measurements obtained with the non-contact tonometer Corvis Scheimpflug Technology (Corvis ST, OCULUS, Wetzlar, Germany) versus Goldmann applanation tonometry (GAT) and ultrasound-based corneal pachymetry (US-CCT).Eye healthy participants, patients with ocular hypertension (OHT) and patients with open-angle glaucoma were included in this prospective study. In each participant, GAT, US-CCT and measurements with Corvis ST were obtained (Corvis-IOP and Corvis-CCT). Accuracy and repeatability were tested by correlation and regression analyses, Bland-Altman plots and assessment of intraclass correlation coefficients.A consecutive series of 188 right study eyes of 188 participants (142 eyes with glaucoma, 10 eyes with OHT and 36 control eyes) were included in this prospective study. The mean GAT of all included was 14.5±4.8 mm Hg compared with mean Corvis-IOP of 15.4±5.6 mm Hg (Spearman's r=0.75, p0.0001). Mean US-CCT was 544.56±40.0 µm compared with Corvis-CCT of 545.2±46.5 µm (Pearson's r=0.78, p0.0001). Bland-Altman plots of all included eyes as well as subgroup analyses revealed good agreement of the IOP and CCT measurement techniques. High intraclass correlation coefficient values in 17 patients with repeated measurements revealed very good repeatability (0.942 and 0.937 for Corvis-IOP and Corvis-CCT, respectively). Corvis-IOP but not GAT showed a trend of dependence on CCT.Obtaining CCT and measuring IOP with the Corvis ST reveals very good repeatability and good accuracy in healthy subjects and patients with OHT and glaucoma when compared with standardised US pachymetry or GAT.

Background Cumulative light exposure is significantly associated with progression of age-related macular degeneration (AMD). Inhibition of vascular endothelial growth factor is the main target of current antiangiogenic treatment strategies in AMD. However, other growth factors, such as platelet-derived growth factor (PDGF) and placenta growth factor (PlGF), have a substantial impact on development of AMD. Previous reports indicate that sorafenib, an oral multikinase inhibitor, might have beneficial effects on exudative AMD. This study investigates the effects of sorafenib on lightinduced overexpression of growth factors in human retinal pigment epithelial (RPE) cells. Methods Primary human RPE cells were exposed to white light and incubated with sorafenib. Viability, expression, and secretion of VEGF-A, PDGF-BB, and PlGF and their mRNA were determined by reverse transcription-polymerase chain reactions, immunohistochemistry and enzyme-linked immunosorbent assays. Results Light exposure decreased cell viability and increased expression and secretion of VEGF-A, PDGF-BB and PlGF. These light-induced effects were significantly reduced when cells were treated with sorafenib at a dose of 1 mg/ml. Conclusion The results show that sorafenib has promising properties as a potential antiangiogenic treatment for AMD.